At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Nowarta110 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Two- Staged Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Nowarta110 in Patients With Plantar Warts and Clinical Recovery Successfully Completed
In Brief
A Phase 2 clinical trial evaluating Nowarta110 and Placebo for Plantar Warts. Completed, enrolled 54 participants across 1 site.
Detailed Summary
To evaluate drug safety and efficacy in patients treated with Nowarta110 and to determine therapeutic activity against Plantar Warts * Clinical Tolerance * Clinical Recovery * Evaluate Safety
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlantar Warts
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartFeb 2015
Primary CompletionSep 2015
Study CompletionDec 2015
TodayJul 2026
First PostedJan 14, 2015
Enrollment StartFeb 1, 2015
Primary CompletionSep 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.5 years ago
Interventions
Nowarta110drug
Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
Placebodrug
Matching placebo liquid for topic administration.